Market Overview

Piper Jaffray Impressed By New Regeneron Drugs (REGN)


Piper Jaffray analysts Chad Messer and Edward Tenthoff visited Regeneron (NADAQ:REGN) yesterday, where they were impressed by the biotech company's new product lines.

Piper Jaffray said, "Regeneron fits our thesis that well financed biotech companies with innovative drug launches over the next 2 years will re-populate large cap ranks and outperform."

Regeneron has 3 drugs with multiple data readouts in the next one and a half years: Arcalyst, Aflibercept and VEGF Trap Eye. Piper Jaffray projects a $2.6 billion enterprise value for all three drugs.

Regeneron also has a productive antibody pipeline funded by Sanofi.

Regeneron is rated Outperform by Piper Jaffray, with a price target of $35.00. REGN is currently trading at $22.32.

Posted-In: Chad Messer Edward Tenthoff Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles

View Comments and Join the Discussion!

Latest Ratings

ABBBarclaysInitiates Coverage On
DPLOWilliam BlairUpgrades
SUPVItau BBADowngrades
GGALItau BBADowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

June Monster Employment Index Rises 21% v. 2009

Markets in Everything: Renting White People